Seres Therapeutics Presents Data Across Broad Microbiome Pipeline

 Data validates strength of Seres’ investigational microbiome therapeutics pipeline in potentially addressing unmet treatment needs in recurrent C. difficile infection and ulcerative colitis –

– In Phase 3 ECOSPOR III study, SER-109 significantly reduced recurrence rates of C. difficile infection at 24 weeks with an observed safety profile comparable to placebo –

– Preclinical data support the potential of SER-301 as a therapeutic modality for mild-to-moderate ulcerative colitis through microbiome restoration –

https://finance.yahoo.com/news/seres-therapeutics-presents-data-across-161500780.html